

Breast Cancer[®]

U P D A T E

An Audio Review Journal for Oncology Nurses
Management of Breast Cancer in the Adjuvant and Metastatic Settings

EDITOR

Neil Love, MD

FACULTY

Clifford Hudis, MD

John Mackey, MD

Maureen Major, RN, MS

*Additional comments by a
woman with breast cancer*



A Continuing Nursing Education (CNE) Audio Series Activity

STATEMENT OF NEED/TARGET AUDIENCE

Medical oncology, particularly breast cancer, is one of the most rapidly advancing and developing fields of medicine. The constant emergence of new systemic agents, new indications for existing systemic agents, novel therapies, clinical trials and research findings demands that oncology nurses remain dedicated to continuing education in order to offer their patients the best care possible. This program provides registered nurses access to the most up-to-date research developments in breast cancer and the opinions of oncology nurses and research leaders with experience and expertise in the field. This information can be effectively translated into everyday patient management decisions.

PURPOSE STATEMENT

To present the most current research developments in breast cancer and to provide the perspectives of medical oncologists, oncology nurses and patients on the diagnosis and treatment of breast cancer.

EDUCATIONAL OBJECTIVES FOR THIS ISSUE OF *BREAST CANCER UPDATE FOR ONCOLOGY NURSES*

- Discuss the clinical implications of emerging clinical trial data in breast cancer treatment and how to incorporate these data into management strategies in the adjuvant, neoadjuvant, metastatic and preventive settings.
- Describe ongoing clinical trials available to patients with breast cancer.
- Explain the risks and benefits of adjuvant aromatase inhibitors and of sequencing aromatase inhibitors after tamoxifen in postmenopausal patients with ER-positive breast cancer.
- Review the risks and benefits of adjuvant ovarian suppression alone or with other endocrine interventions.
- Describe an algorithm for HER2 testing and treatment of patients with HER2-positive breast cancer in the adjuvant, neoadjuvant and metastatic settings.
- Discuss the selection and sequencing of endocrine therapy in appropriate patients with metastatic disease.
- Describe the risks and benefits of combination versus single-agent chemotherapy.
- Describe the computerized risk models and genetic markers to determine prognostic information on the quantitative risk of breast cancer relapse.
- Explain the risks and benefits of incorporating bevacizumab into standard chemotherapy for the management of metastatic disease.

ACCREDITATION STATEMENTS

CNA/ANCC

This educational activity for 3.3 contact hours is provided by Postgraduate Institute for Medicine (PIM). PIM is an approved provider of continuing education by the Colorado Nurses Association, an accredited approver by the American Nurses Credentialing Center's Commission on Accreditation.

California Board of Registered Nursing

Postgraduate Institute for Medicine is approved by the California Board of Registered Nursing, Provider Number 13485, for 3.3 contact hours.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed post-test with a score of 70% or better. Your statement of credit will be mailed to you within three weeks.

HOW TO USE THIS CNE ACTIVITY

This is an audio CNE activity. This book contains a continuing nursing education post-test, and the corresponding website www.BreastCancerUpdate.com/Nurses includes links to relevant full-text articles and abstracts. There are no fees for participating and receiving CNE credit for this activity. To receive credit during the period of March 2006 through March 2007, participants should read the learning objectives and faculty disclosures, listen to the CDs, review the internet references and complete the post-test and evaluation form located in the back of this book or on the www.BreastCancerUpdate.com/Nurses website and mail or fax the evaluation form to Postgraduate Institute for Medicine.

Breast Cancer®

U P D A T E

FACULTY AFFILIATIONS



Clifford Hudis, MD

Chief, Breast Cancer
Medicine Service
Solid Tumor Division
Memorial Sloan-Kettering
Cancer Center
New York, New York



Maureen Major, RN, MS

Clinical Nurse Specialist
Evelyn H Lauder Breast Center
Memorial Sloan-Kettering
Cancer Center
New York, New York



John Mackey, MD

Medical Oncologist, Cross Cancer Institute
Associate Professor of Oncology
University of Alberta
Chair, Northern Alberta Breast Cancer Program
Director, Cancer International Research Group
Edmonton, Canada

CONTENT VALIDATION AND DISCLOSURES

Postgraduate Institute for Medicine (PIM) assesses conflict of interest with its instructors, planners, managers and other individuals who are in a position to control the content of CME activities. All relevant conflicts of interest that are identified are thoroughly vetted by PIM for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. PIM is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Dr Hudis — Consulting Fees: Amgen Inc, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Genentech BioOncology, Novartis Pharmaceuticals, Pfizer Inc, Roche Laboratories Inc; Contracted Research: Amgen Inc, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Genentech BioOncology, Kosan Biosciences, Novartis Pharmaceuticals, Pfizer Inc, Roche Laboratories Inc; Ownership Interest: Genomic Health Inc. **Dr Mackey** — Consulting Fees and Speaking Honoraria: Amgen Inc, AstraZeneca Pharmaceuticals LP, Pfizer Inc, Roche Laboratories Inc, Sanofi-Aventis. **Ms Major** — Speakers Bureau: Abraxis Oncology, Amgen Inc, Genentech BioOncology.

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Richard Kaderman, PhD, Neil Love, MD, Douglas Paley, Michelle Paley, MD, Margaret Peng, Lillian Sklaver Paltorack, PharmD and Kathryn Ault Ziel, PhD — no real or apparent conflicts of interest to report; Sally Bogert, RNC, WHCNP — shareholder of Amgen Inc. Research To Practice receives education grants from Abraxis Oncology, Amgen Inc, AstraZeneca Pharmaceuticals LP, Biogen Idec, Genentech BioOncology, Genomic Health Inc, Roche Laboratories Inc and Sanofi-Aventis, who have no influence on the content development of our educational activities.

The following PIM clinical content reviewers, Jan Hixon, RN; Linda Graham, RN; and Trace Hutchison, PharmD, state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interests related to the content of this CNE activity of any amount during the past 12 months.

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Postgraduate Institute for Medicine (PIM), Research To Practice, Abraxis Oncology, AstraZeneca Pharmaceuticals LP, Genentech BioOncology and Genomic Health Inc do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of PIM, Research To Practice, Abraxis Oncology, AstraZeneca Pharmaceuticals LP, Genentech BioOncology or Genomic Health Inc. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings.

Breast Cancer Update for Oncology Nurses — Issue 1, 2006**QUESTIONS (PLEASE CIRCLE ANSWER):**

1. Aromatase inhibitors can be effective in _____ patients with ER-positive breast cancer.
 - a. Premenopausal
 - b. Postmenopausal
 - c. Both pre- and postmenopausal
2. Aromatase inhibitors inhibit the enzyme aromatase, which normally converts androgens from the adrenal glands into estrogens.
 - a. True
 - b. False
3. Which agent is superior in disease-free survival in the trials comparing aromatase inhibitors to tamoxifen in the adjuvant setting?
 - a. Tamoxifen
 - b. Aromatase inhibitors
4. Which of the following adverse events occur less frequently with anastrozole than with tamoxifen?
 - a. Endometrial cancer
 - b. Fractures
 - c. Thromboembolic events
 - d. Both a and b
 - e. Both a and c
5. In the ECOG-E2100 trial, the addition of bevacizumab to paclitaxel significantly _____ response rate and the duration of progression-free survival.
 - a. Increased
 - b. Decreased
6. Patients with node-negative, ER-positive disease and a high recurrence score, according to the *Oncotype DX*TM assay, have been shown to benefit from adjuvant _____.
 - a. Tamoxifen
 - b. Anastrozole
 - c. Fulvestrant
 - d. Chemotherapy
7. Which endocrine agent is given by intramuscular injection and has few side effects?
 - a. Tamoxifen
 - b. Anastrozole
 - c. Letrozole
 - d. Fulvestrant
8. Five clinical trials have reported that adjuvant trastuzumab given to a patient with HER2-positive breast cancer reduces her risk of recurrence by approximately _____.
 - a. 10 percent
 - b. 20 percent
 - c. 30 percent
 - d. 40 percent
 - e. 50 percent
9. In the BCIRG 006 trial, the combination of docetaxel, carboplatin and trastuzumab in the adjuvant setting reduced the risk of recurrence without increasing the risk of congestive heart failure.
 - a. True
 - b. False
10. Which of the following measures can reduce a patient's risk of osteoporosis when the patient is taking aromatase inhibitors?
 - a. Exercise
 - b. Calcium supplementation
 - c. Bisphosphonates
 - d. All of the above
 - e. None of the above
11. In the Women's Intervention Nutrition Study (WINS), women randomly assigned to the dietary intervention group had a significantly lower incidence of breast cancer relapse.
 - a. True
 - b. False
12. The *Oncotype DX* assay can be used to determine the risk of distant recurrence at 10 years in tamoxifen-treated patients with node-negative, ER-positive breast cancer.
 - a. True
 - b. False
13. In a study conducted by Lesley Fallowfield, approximately _____ of patients preferred an intramuscular injection versus an oral agent in the treatment of metastatic disease.
 - a. Five percent
 - b. 10 to 15 percent
 - c. 25 to 30 percent
 - d. 66 percent

EVALUATION FORM

Breast Cancer Update for Oncology Nurses — Issue 1, 2006

Postgraduate Institute for Medicine (PIM) respects and appreciates your opinions. To assist us in evaluating the effectiveness of this activity and to make recommendations for future educational offerings, please take a few minutes to complete this evaluation form. You must complete this evaluation form to receive acknowledgment of participation for this activity.

Please answer the following questions by circling the appropriate rating:

5 = Outstanding 4 = Good 3 = Satisfactory 2 = Fair 1 = Poor

EXTENT TO WHICH PROGRAM ACTIVITIES MET THE IDENTIFIED GOAL

- To present the most current research developments in breast cancer and to provide the perspectives of medical oncologists, oncology nurses and patients on the diagnosis and treatment of breast cancer. 5 4 3 2 1

EXTENT TO WHICH PROGRAM ACTIVITIES MET THE IDENTIFIED OBJECTIVES

Upon completion of this activity, participants should be better able to:

- Discuss the clinical implications of emerging clinical trial data in breast cancer treatment and how to incorporate these data into management strategies in the adjuvant, neoadjuvant, metastatic and preventive settings. 5 4 3 2 1
- Describe ongoing clinical trials available to patients with breast cancer. 5 4 3 2 1
- Explain the risks and benefits of adjuvant aromatase inhibitors and of sequencing aromatase inhibitors after tamoxifen in postmenopausal patients with ER-positive breast cancer. 5 4 3 2 1
- Review the risks and benefits of adjuvant ovarian suppression alone or with other endocrine interventions. 5 4 3 2 1
- Describe an algorithm for HER2 testing and treatment of patients with HER2-positive breast cancer in the adjuvant, neoadjuvant and metastatic settings. 5 4 3 2 1
- Discuss the selection and sequencing of endocrine therapy in appropriate patients with metastatic disease. 5 4 3 2 1
- Describe the risks and benefits of combination versus single-agent chemotherapy. 5 4 3 2 1
- Describe the computerized risk models and genetic markers to determine prognostic information on the quantitative risk of breast cancer relapse. 5 4 3 2 1
- Explain the risks and benefits of incorporating bevacizumab into standard chemotherapy for the management of metastatic disease. 5 4 3 2 1

EFFECTIVENESS OF THE INDIVIDUAL FACULTY MEMBERS

Faculty	Knowledge of subject matter	Effectiveness as an educator
Clifford Hudis, MD	5 4 3 2 1	5 4 3 2 1
John Mackey, MD	5 4 3 2 1	5 4 3 2 1
Maureen Major, RN, MS	5 4 3 2 1	5 4 3 2 1

OVERALL EFFECTIVENESS OF THE ACTIVITY

- Will assist me in improving patient care. 5 4 3 2 1
- Fulfilled my educational needs. 5 4 3 2 1
- Avoided commercial bias or influence. 5 4 3 2 1

IMPACT OF THE ACTIVITY

The information presented (check all that apply):

- Reinforced my current practice/treatment habits. Enhanced my current knowledge base.

Breast Cancer Update for Oncology Nurses — Issue 1, 2006

IMPACT OF THE ACTIVITY (CONTINUED)

Will the information presented cause you to make any changes in your practice?

- Yes No

If yes, please describe any change(s) you plan to make in your practice as a result of this activity:

.....
.....

How committed are you to making these changes?

(5 = very committed; 1 = not at all committed) 5 4 3 2 1

FUTURE ACTIVITIES

Do you feel future activities on this subject matter are necessary and/or important to your practice?

- Yes No

Please list any other topics that would be of interest to you for future educational activities:

.....
.....

Additional comments about this activity:

.....
.....

FOLLOW-UP

As part of our ongoing, continuous, quality-improvement effort, we conduct postactivity follow-up surveys to assess the impact of our educational interventions on professional practice. Please indicate your willingness to participate in such a survey:

- Yes, I am willing to participate in a follow-up survey. No, I am not willing to participate in a follow-up survey.

REQUEST FOR CREDIT — please print clearly

Name: Degree:

Organization: Specialty:

Address:

City, State, Zip:

Telephone: Fax: Email:

Signature: Date:

To receive acknowledgment of participation in this activity, please complete the post-test and this evaluation/verification of participation and FAX to: (303) 790-4876 or mail to Postgraduate Institute for Medicine, 367 Inverness Parkway, Suite 225, Englewood, CO 80112. The post-test and evaluation may also be completed on the www.BreastCancerUpdate.com/Nurses website.

Breast Cancer®

U P D A T E

Editor	Neil Love, MD
Associate Editors	Michelle Paley, MD Richard Kaderman, PhD Kathryn Ault Ziel, PhD
Writers	Lillian Sklaver Poltorack, PharmD Sally Bogert, RNC, WHCNP Douglas Paley
CME Director	Michelle Paley, MD
Content Validation	Margaret Peng
Director, Creative and Copy Editing	Aura Herrmann
Creative Manager	Fernando Rendina
Design Quality Control Director	Ben Belin
Associate Designer	Maria Agudelo-Schaefer
Graphic Designer	Jason Cunniss
Junior Designer	Shantia Daniel
Senior Production Editor	Alexis Oneca
Traffic Coordinator	Tere Sosa
Copy Editors	Joy Davis Mary DiNunzio Rosemary Hulce Pat Morrissey/Havlin Carol Peschke Susan Petrone
Production Manager	Patricia Kappes
Audio Production	Frank Cesarano
Technical Services	Arly Ledezma
Web Master	John Ribeiro
Editorial Assistants	Catherine Marshall Patricia McWhorter Christina Rodriguez Ginelle Suarez
Contact Information	Neil Love, MD Research To Practice One Biscayne Tower 2 South Biscayne Boulevard, Suite 3600 Miami, FL 33131 Fax: (305) 377-9998 Email: NLove@ResearchToPractice.net
For CME Information	Email: CME@ResearchToPractice.net

Copyright © 2006 Research To Practice. All rights reserved.

This program is supported by education grants from Abraxis Oncology, AstraZeneca Pharmaceuticals LP, Genentech BioOncology and Genomic Health Inc.

The compact discs, internet content and accompanying printed material are protected by copyright. No part of this program may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording or utilizing any information storage and retrieval system, without written permission from the copyright owner.

The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management.

Any procedures, medications or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications or dangers in use, review of any applicable manufacturer's product information and comparison with recommendations of other authorities.

Breast Cancer®

U P D A T E

Copyright © 2006 Research To Practice.

This program is supported by education grants from Abraxis Oncology, AstraZeneca Pharmaceuticals LP, Genentech BioOncology and Genomic Health Inc.



Co-sponsored by Postgraduate Institute for Medicine and Research To Practice.

Last review date: March 2006

Release date: March 2006

Expiration date: March 2007

Estimated time to complete: 2 hours, 45 minutes